Showing results (3131-3140 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 16, 2010
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cellsNorma O'Donovan, Annette T Byrne, Aisling E O'Connor, et al.
Investigational New Drugs|February 2, 2010
Proposal for size justification of expanded cohort at phase-2-recommended doseNicolas Penel, Charles Fournier, Jocelyne Bérille
Investigational New Drugs|June 2, 2018
The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United StatesHiroki Nakayama, Naoki Matsumaru, Katsura Tsukamoto
Investigational New Drugs|June 2, 2018
GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell deathJuliana Carvalho Alves-Silva, Juliana Lott de Carvalho, Doralina Amaral Rabello, et al.
Investigational New Drugs|January 1, 1985
Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicityR F Novak, E D Kharasch
Investigational New Drugs|July 12, 2018
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinomaMasafumi Ikeda, Manabu Morimoto, Masaomi Tajimi, et al.
Investigational New Drugs|July 13, 2018
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell linesEsther Amalia Guzmán, Tara Peterson Pitts, Maria Cristina Diaz, et al.
Investigational New Drugs|June 28, 2018
Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell typesCijo George Vazhappilly, Ekram Saleh, Wafaa Ramadan, et al.
Investigational New Drugs|June 28, 2018
Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective studyCassia Regina Guedes Leal, Cristiane Magalhães, Daniel Barbosa, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
Pageof 372